In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Catherine Longworth

Catherine Longworth is a reporter covering commercial and R&D developments in the medtech industry. A graduate of St. George's, University of London, Catherine holds a BSc in Biomedical Science. Before joining Informa, she worked in the editorial team at Pharmaceutical Press, the publishing division of the Royal Pharmaceutical Society, where she wrote and edited for a number of pharmaceutical publications. After gaining experience in the world of scientific publishing, Catherine took the leap to study a postgraduate qualification in journalism. During the course, she carried out placements with local London newspapers, writing general news and building her portfolio by reporting on a wide range of current affairs such as the European migrant crisis, political protests and the London mayoral election. Catherine is passionate about human rights and is fascinated by the innovative nature of the medtech industry and the healthcare advances that have the greatest benefit to mankind. She lives in London and loves music, arts, travel, writing, reading and is always happy to receive recommendations for books or places to travel!

Advertisement
Set Alert for Articles By Catherine Longworth

Latest From Catherine Longworth

QuantumMDx And Glaxo Smith Kline Partner On QC Analyzer For Cell And Gene Therapies

QuantumMDx Group Ltd has signed a deal with GlaxoSmithKline to co-develop a quality control analytics system for cell and gene therapies.

Commercial Companies

SOPHiA GENETICS Secures CE Mark For Solid Tumor Solution Product

SOPHiA GENETICS has scored a CE-IVD mark for its molecular diagnostic device, Solid Tumor Solution (STS). 

Cancer Commercial

US FTC Approves Fresenius And NxStage Merger

The US Federal Trade Commission has finally approved Fresenius' $2bn acquisition of NxStage Medical. A complaint filed by the FTC in February 2019 claimed the deal would be anti-competitive.

M & A Deals

Device Week, April 10, 2019 – Alcon Is Finally Free From Novartis; EOS Promotes 3D Ortho-Imaging At AAOS

In this edition of Device Week, Catherine Longworth reports on eye-care giant Alcon's $28bn spin-off from Novartis. Marion Webb reviews her interview with executives from EOS imaging SA, a developer of imaging medical devices for orthopedics.

Device Week M & A

All 'Bye' Itself: Alcon Spins Out From Novartis In $25Bn Stock Listing

Alcon is going it alone following a spin-out from Swiss pharma giant Novartis. The eye-care device business officially listed on the SIX Stock Exchange on April 9 with a total market capitalization of around $28bn, making it Switzerland's biggest stock deal in a decade. 

Ophthalmology Commercial

Inside ALYN Innovation, Israel’s One-Stop Shop For Pediatric Rehab Tech

Israel’s only pediatric and adolescent rehabilitation facility, ALYN Hospital, hopes to pioneer new assistive technologies to help children with special needs. The unique one-stop shop for entrepreneurs is focusing on prototyping and developing rehabilitation solutions that can be brought to an international market. 

Commercial Innovation
See All
Advertisement
UsernamePublicRestriction

Register